Discover 1,123 paid clinical trials in Alabama. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Alabama provides a diverse range of research opportunities for healthy volunteers and individuals with specific health conditions. Leading research centers in Birmingham, Montgomery, and Mobile are seeking participants, offering access to innovative treatments and cutting-edge medical care.
Filter
1
Filter results
Results: 1,123
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
for
Atherosclerosis, Coronary Artery Disease
Location: Camp Hill PA, Hialeah FL, St. Petersburg FL,
Sponsor: Beijing Inno Medicine Co., Ltd.
Sex: All
Age: 18 - 70+
Code: NCT07521007
Phase 2, Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
for
Primary Membranous Nephropathy
Location: New York NY, Miami FL, Winter Park FL, Orlando FL,
Sponsor: Vertex Pharmaceuticals Incorporated
Sex: All
Age: 18 - 70+
Code: NCT07204275
Phase 2, Phase 3, Recruiting
Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)
for
Stickler Syndrome Type 1, Stickler Syndrome Type 2
Location: Royal Oak MI, Birmingham AL, Nashville TN, Rochester MN,
Sponsor: Helen Keller Eye Research Foundation
Sex: All
Age: 0+
Code: NCT07146516
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Boston MA, New York NY, Hackensack NJ,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06973187
Phase 3, Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Get alerts for new trials in your area by subscribing now
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
for
Hidradenitis Suppurativa
Location: New York NY, Montreal, Quebec, Vienna VA, Rochester NY,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT07665437
Phase 3, Recruiting
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
for
Epithelial Ovarian Cancer, Fallopian Tube Cancer,
Location: Providence RI, New Haven CT, Lebanon NH, Bay Shore NY,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT06890338
Phase 2, Recruiting
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
for
Non-muscle Invasive Bladder Cancer
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07206225
Phase 1, Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Location: Chicoutimi, New York NY, Summit NJ, New Brunswick NJ,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT06989437
Phase 2, Phase 3, Recruiting
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
for
Acute Migraine
Location: Boston MA, Waltham MA, Waterbury CT, Commack NY,
Sponsor: TriGemX Bio, Inc.
Sex: All
Age: 18+
Code: NCT07674654
Phase 3, Recruiting
Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities
for
Cardiovascular, Comorbidity, Diabetes,
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 50 - 70+
Code: NCT07748858
Recruiting
A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies
for
HIV
Location: Boston MA, Atlanta GA, Birmingham AL, Seattle WA
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)